Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ...
Abstract Mefatinib (MET306) is a novel second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) designed to address the highly unmet clinical need of gefitinib-induced resistance and irreversibly bind to mutated tyrosine kinase domain of EGFR and human epidermal growth...
Main Authors: | , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | unknown |
Published: |
figshare
2022
|
Subjects: | |
Online Access: | https://dx.doi.org/10.6084/m9.figshare.c.6299923 https://springernature.figshare.com/collections/Development_and_validation_of_a_new_LC_MS_MS_method_for_the_determination_of_mefatinib_in_human_plasma_and_its_first_application_in_pharmacokinetic_studies/6299923 |
id |
ftdatacite:10.6084/m9.figshare.c.6299923 |
---|---|
record_format |
openpolar |
spelling |
ftdatacite:10.6084/m9.figshare.c.6299923 2024-04-28T08:32:27+00:00 Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... Xu, Yichao Chen, Jinliang Shao, Rong Ruan, Zourong Jiang, Bo Lou, Honggang 2022 https://dx.doi.org/10.6084/m9.figshare.c.6299923 https://springernature.figshare.com/collections/Development_and_validation_of_a_new_LC_MS_MS_method_for_the_determination_of_mefatinib_in_human_plasma_and_its_first_application_in_pharmacokinetic_studies/6299923 unknown figshare Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 Biochemistry Space Science Medicine Cell Biology Genetics FOS Biological sciences Biological Sciences not elsewhere classified Developmental Biology Infectious Diseases FOS Health sciences Collection article 2022 ftdatacite https://doi.org/10.6084/m9.figshare.c.6299923 2024-04-02T12:06:38Z Abstract Mefatinib (MET306) is a novel second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) designed to address the highly unmet clinical need of gefitinib-induced resistance and irreversibly bind to mutated tyrosine kinase domain of EGFR and human epidermal growth factor receptor 2 (HER2). In this study, a liquid chromatography–tandem mass spectrometry method was established and validated for determining MET306 in non-small cell lung cancer patients and a backpropagation artificial neural network was developed and constructed to predict the pharmacokinetic process. The mobile phase was water containing 5 mM ammonium acetate and acetonitrile at a flow rate of 0.3 mL min−1, within a 4.5 min run time. MET306 was separated on a Hypersil Gold-C18 at 40 °C and subjected to mass analysis using positive electrospray ionization. A total of 524 data were used as development groups and 145 data were used as testing groups. The final established Northern Goshawk ... Article in Journal/Newspaper Northern Goshawk DataCite Metadata Store (German National Library of Science and Technology) |
institution |
Open Polar |
collection |
DataCite Metadata Store (German National Library of Science and Technology) |
op_collection_id |
ftdatacite |
language |
unknown |
topic |
Biochemistry Space Science Medicine Cell Biology Genetics FOS Biological sciences Biological Sciences not elsewhere classified Developmental Biology Infectious Diseases FOS Health sciences |
spellingShingle |
Biochemistry Space Science Medicine Cell Biology Genetics FOS Biological sciences Biological Sciences not elsewhere classified Developmental Biology Infectious Diseases FOS Health sciences Xu, Yichao Chen, Jinliang Shao, Rong Ruan, Zourong Jiang, Bo Lou, Honggang Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
topic_facet |
Biochemistry Space Science Medicine Cell Biology Genetics FOS Biological sciences Biological Sciences not elsewhere classified Developmental Biology Infectious Diseases FOS Health sciences |
description |
Abstract Mefatinib (MET306) is a novel second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) designed to address the highly unmet clinical need of gefitinib-induced resistance and irreversibly bind to mutated tyrosine kinase domain of EGFR and human epidermal growth factor receptor 2 (HER2). In this study, a liquid chromatography–tandem mass spectrometry method was established and validated for determining MET306 in non-small cell lung cancer patients and a backpropagation artificial neural network was developed and constructed to predict the pharmacokinetic process. The mobile phase was water containing 5 mM ammonium acetate and acetonitrile at a flow rate of 0.3 mL min−1, within a 4.5 min run time. MET306 was separated on a Hypersil Gold-C18 at 40 °C and subjected to mass analysis using positive electrospray ionization. A total of 524 data were used as development groups and 145 data were used as testing groups. The final established Northern Goshawk ... |
format |
Article in Journal/Newspaper |
author |
Xu, Yichao Chen, Jinliang Shao, Rong Ruan, Zourong Jiang, Bo Lou, Honggang |
author_facet |
Xu, Yichao Chen, Jinliang Shao, Rong Ruan, Zourong Jiang, Bo Lou, Honggang |
author_sort |
Xu, Yichao |
title |
Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
title_short |
Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
title_full |
Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
title_fullStr |
Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
title_full_unstemmed |
Development and validation of a new LC–MS/MS method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
title_sort |
development and validation of a new lc–ms/ms method for the determination of mefatinib in human plasma and its first application in pharmacokinetic studies ... |
publisher |
figshare |
publishDate |
2022 |
url |
https://dx.doi.org/10.6084/m9.figshare.c.6299923 https://springernature.figshare.com/collections/Development_and_validation_of_a_new_LC_MS_MS_method_for_the_determination_of_mefatinib_in_human_plasma_and_its_first_application_in_pharmacokinetic_studies/6299923 |
genre |
Northern Goshawk |
genre_facet |
Northern Goshawk |
op_rights |
Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 |
op_doi |
https://doi.org/10.6084/m9.figshare.c.6299923 |
_version_ |
1797589640592490496 |